ClinicalTrials.gg
CompletedNCT05408429Updated Sep 19, 2024Results posted

Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13

A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 43 sites in 3 countries. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
12 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
16th of 19
356 · median 668
Started
2022
with 2 others
Phase 3
14 of 19
1 open now
Registered
11th of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 16th largest by enrollment, is one of 3 that started in 2022, is one of 14 in phase 3, and was the 11th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 12 Months to 23 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in toddlers who had 2 prior doses of Prevnar 13.

This study is being conducted in children who:

  • are between 12 to 23 months of age;
  • are healthy as determined by the study doctors;
  • have received 2 doses of Prevnar 13 during the first year in life.

Participants in this study will receive either 1 dose or 2 doses of the study vaccine or 1 dose of Prevnar 13 as a shot in the muscle. During the study, participants will have to come to the study clinic to receive the vaccines and have blood sample collected. The study team will work with participants' parents or legal guardians to monitor any unwanted reactions to the vaccines. Participants are expected to take part in this study for about 1 or 3 months, for 1 dose or 2 dose schedules, respectively.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
12 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female toddlers ≥12 to \<24 months of age at the time of consent
  • Healthy toddlers determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study
  • 2 infant doses of Prevenar 13 prior to 12 months of age

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)
  • Major known congenital malformation or serious chronic disorder
  • Other chronic medical or laboratory abnormality that may increase the risk associated with study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Previous vaccination with any pneumococcal vaccine, or planned receipt through study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
356 participants (actual)

Study arms

  • Experimental
    2-Dose 20vPnC Group

    Pneumococcal conjugate vaccine (2 doses approximately 2 months apart)

    Biological: 20-valent pneumococcal conjugate vaccine

  • Experimental
    1-Dose 20vPnC Group

    Pneumococcal conjugate vaccine

    Biological: 20-valent pneumococcal conjugate vaccine

  • Active comparator
    13vPnC Group

    Pneumococcal conjugate vaccine

    Biological: 13-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 7 Days After Last Vaccination

    Local reactions included redness, swelling, and pain at the injection site, recorded by parents/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit = 0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.

    Time frame: Within 7 days after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)

  2. Percentage of Participants With Systemic Events Within 7 Days After Last Vaccination

    Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.

    Time frame: Within 7 days after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)

  3. Percentage of Participants With Adverse Events (AEs) From Last Vaccination to 1 Month After Last Vaccination

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. 95% CI was based on the Clopper and Pearson method. AEs reported in this endpoint excluded local reactions and systemic events collected from an e-diary.

    Time frame: From last vaccination to 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)

  4. Percentage of Participants With Serious Adverse Events (SAEs) From Last Vaccination to 1 Month After Last Vaccination

    A SAE was any untoward medical occurrence that: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, was considered serious and other important medical events. 95% CI was based on the Clopper and Pearson method.

    Time frame: From last vaccination to 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)

  5. Percentage of Participants With Predefined Serotype-Specific Immunoglobulin G (IgG) Concentrations for the 7 Additional Serotypes 1 Month After Last Vaccination

    Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 7 additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, 33F. The predefined level was 0.35 microgram per milliliter (mcg/mL) for all 7 additional serotypes. 95% CI was based on the Clopper and Pearson method.

    Time frame: 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)

Secondary outcomes

  1. Serotype-specific IgG Geometric Mean Concentrations (GMC) 1 Month After Last Vaccination

    Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and 7 additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, 33F. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, corresponding 2-sided 95% CIs (based on Student's t distribution).

    Time frame: 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)

  2. Percentage of Participants With Predefined IgG Concentrations for the 13 Matched Serotypes 1 Month After Last Vaccination

    Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes:1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C,19A,19F, 23F. Predefined level was 0.35 mcg/mL for all 13vPnC serotypes except serotypes 5, 6B, and 19A, which had predefined levels of 0.23, 0.10, and 0.12 mcg/mL, respectively. 95% CI was based on the Clopper and Pearson method.

    Time frame: 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)

  3. Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Last Vaccination

    OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after last vaccination received. OPA titers below the LLOQ were set to 0.5\*LLOQ. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the Student's t distribution.

    Time frame: 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)

07

Results

Posted Sep 19, 2024

Participant flow

Participants included in this study were toddlers greater than or equal to (\>=) 12 to less than (\<) 24 months of age who had received 2 doses of 13-valent pneumococcal conjugate vaccine (13vPnC) (Prevenar 13) in infancy (prior to 12 months of age).

Participant flow — Overall Study
Milestone2-Dose 20vPnC1-Dose 20vPnC13vPnC Control
Started121118117
Completed115117116
Not completed611
Withdrew: Lost to follow-up110
Withdrew: Withdrawal by subject501

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 7 Days After Last Vaccination

Local reactions included redness, swelling, and pain at the injection site, recorded by parents/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit = 0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.

Time frame:
Within 7 days after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Last Vaccination
Percentage of participants2-Dose 20vPnC1-Dose 20vPnC13vPnC Control
Redness: Any26.3 ± 18.529.7 ± 21.632.5 ± 24.1
Redness: Mild13.2 ± 7.618.6 ± 12.117.9 ± 11.5
Redness: Moderate12.3 ± 6.911.0 ± 6.014.5 ± 8.7
Redness: Severe0.9 ± 0.00 ± 0.00 ± 0.0
Swelling: Any23.7 ± 16.221.2 ± 14.225.6 ± 18.0
Swelling: Mild14.0 ± 8.212.7 ± 7.316.2 ± 10.1
Swelling: Moderate8.8 ± 4.38.5 ± 4.19.4 ± 4.8
Swelling: Severe0.9 ± 0.00 ± 0.00 ± 0.0
Pain at Injection Site: Any29.8 ± 21.628.8 ± 20.831.6 ± 23.3
Pain at Injection Site: Mild17.5 ± 11.117.8 ± 11.426.5 ± 18.8
Pain at Injection Site: Moderate12.3 ± 6.911.0 ± 6.05.1 ± 1.9
Pain at Injection Site: Severe0 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Last Vaccination

Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.

Time frame:
Within 7 days after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Last Vaccination
Percentage of participants2-Dose 20vPnC1-Dose 20vPnC13vPnC Control
Fever: >=38.0 degrees C9.6 ± 4.915.3 ± 9.315.4 ± 9.4
Fever: >38.0 degrees C to 38.4 degrees C3.5 ± 1.06.8 ± 3.010.3 ± 5.4
Fever: >38.4 degrees C to 38.9 degrees C4.4 ± 1.43.4 ± 0.92.6 ± 0.5
Fever: >38.9 degrees C to 40.0 degrees C1.8 ± 0.25.1 ± 1.92.6 ± 0.5
Fever: >40.0 degrees C0 ± 0.00 ± 0.00 ± 0.0
Decreased appetite: Any25.4 ± 17.733.1 ± 24.726.5 ± 18.8
Decreased appetite: Mild14.9 ± 8.915.3 ± 9.312.0 ± 6.7
Decreased appetite: Moderate10.5 ± 5.614.4 ± 8.613.7 ± 8.0
Decreased appetite: Severe0 ± 0.03.4 ± 0.90.9 ± 0.0
Drowsiness/increased sleep: Any23.7 ± 16.232.2 ± 23.931.6 ± 23.3
Drowsiness/increased sleep: Mild18.4 ± 11.825.4 ± 17.921.4 ± 14.3
Drowsiness/increased sleep: Moderate5.3 ± 2.05.9 ± 2.410.3 ± 5.4
Drowsiness/increased sleep: Severe0 ± 0.00.8 ± 0.00 ± 0.0
Irritability: Any55.3 ± 45.750.8 ± 41.546.2 ± 36.9
Irritability: Mild24.6 ± 17.015.3 ± 9.316.2 ± 10.1
Irritability: Moderate29.8 ± 21.632.2 ± 23.929.9 ± 21.8
Irritability: Severe0.9 ± 0.03.4 ± 0.90 ± 0.0
PrimaryPercentage of Participants With Adverse Events (AEs) From Last Vaccination to 1 Month After Last Vaccination

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. 95% CI was based on the Clopper and Pearson method. AEs reported in this endpoint excluded local reactions and systemic events collected from an e-diary.

Time frame:
From last vaccination to 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) From Last Vaccination to 1 Month After Last Vaccination
Percentage of participants2-Dose 20vPnC1-Dose 20vPnC13vPnC Control
Percentage of Participants With Adverse Events (AEs) From Last Vaccination to 1 Month After Last Vaccination22.4 ± 15.224.6 ± 17.125.6 ± 18.0
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) From Last Vaccination to 1 Month After Last Vaccination

A SAE was any untoward medical occurrence that: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, was considered serious and other important medical events. 95% CI was based on the Clopper and Pearson method.

Time frame:
From last vaccination to 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) From Last Vaccination to 1 Month After Last Vaccination
Percentage of participants2-Dose 20vPnC1-Dose 20vPnC13vPnC Control
Percentage of Participants With Serious Adverse Events (SAEs) From Last Vaccination to 1 Month After Last Vaccination0.9 ± 0.00.8 ± 0.00.9 ± 0.0
PrimaryPercentage of Participants With Predefined Serotype-Specific Immunoglobulin G (IgG) Concentrations for the 7 Additional Serotypes 1 Month After Last Vaccination

Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 7 additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, 33F. The predefined level was 0.35 microgram per milliliter (mcg/mL) for all 7 additional serotypes. 95% CI was based on the Clopper and Pearson method.

Time frame:
1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Predefined Serotype-Specific Immunoglobulin G (IgG) Concentrations for the 7 Additional Serotypes 1 Month After Last Vaccination
Percentage of participants2-Dose 20vPnC1-Dose 20vPnC13vPnC Control
Serotype 8100.0 (96.4 to 100.0)98.1 (93.5 to 99.8)8.4 (3.9 to 15.4)
Serotype 10A99.0 (94.7 to 100.0)87.0 (79.2 to 92.7)1.9 (0.2 to 6.5)
Serotype 11A99.0 (94.7 to 100.0)96.3 (90.8 to 99.0)13.0 (7.3 to 20.8)
Serotype 12F91.2 (83.9 to 95.9)54.6 (44.8 to 64.2)0.0 (0.0 to 3.4)
Serotype 15B100.0 (96.4 to 100.0)75.9 (66.7 to 83.6)6.5 (2.6 to 12.9)
Serotype 22F100.0 (96.4 to 100.0)94.4 (88.3 to 97.9)2.8 (0.6 to 7.9)
Serotype 33F99.0 (94.7 to 100.0)83.3 (74.9 to 89.8)3.7 (1.0 to 9.2)
SecondarySerotype-specific IgG Geometric Mean Concentrations (GMC) 1 Month After Last Vaccination

Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and 7 additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, 33F. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, corresponding 2-sided 95% CIs (based on Student's t distribution).

Time frame:
1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Reported as:
Geometric mean · mcg/mL
Serotype-specific IgG Geometric Mean Concentrations (GMC) 1 Month After Last Vaccination
mcg/mL2-Dose 20vPnC1-Dose 20vPnC13vPnC Control
Serotype 11.66 (1.39 to 2.00)2.40 (1.95 to 2.96)3.38 (2.82 to 4.05)
Serotype 30.78 (0.65 to 0.93)0.95 (0.80 to 1.14)1.24 (1.06 to 1.45)
Serotype 43.09 (2.63 to 3.63)4.54 (3.63 to 5.67)5.67 (4.81 to 6.70)
Serotype 51.61 (1.36 to 1.92)2.03 (1.64 to 2.51)2.46 (2.04 to 2.95)
Serotype 6A8.55 (7.25 to 10.07)12.45 (10.16 to 15.27)16.28 (13.48 to 19.66)
Serotype 6B5.17 (4.25 to 6.29)4.87 (3.60 to 6.60)6.64 (5.19 to 8.52)
Serotype 7F4.78 (4.15 to 5.49)4.41 (3.81 to 5.10)6.32 (5.49 to 7.28)
Serotype 9V3.44 (2.96 to 3.99)3.94 (3.29 to 4.71)5.36 (4.55 to 6.31)
Serotype 145.58 (4.66 to 6.68)7.37 (5.85 to 9.29)8.64 (7.01 to 10.64)
Serotype 18C2.84 (2.39 to 3.39)3.13 (2.62 to 3.74)3.78 (3.14 to 4.54)
Serotype 19A3.31 (2.80 to 3.90)6.36 (5.22 to 7.74)6.89 (5.76 to 8.23)
Serotype 19F5.25 (4.38 to 6.28)8.78 (7.04 to 10.94)10.09 (8.33 to 12.22)
Serotype 23F5.06 (4.23 to 6.05)4.45 (3.58 to 5.53)6.32 (5.07 to 7.89)
Serotype 810.16 (8.75 to 11.79)7.56 (6.22 to 9.19)0.05 (0.04 to 0.07)
Serotype 10A6.54 (5.17 to 8.28)1.32 (0.98 to 1.76)0.01 (0.01 to 0.02)
Serotype 11A4.83 (4.11 to 5.68)2.72 (2.17 to 3.41)0.03 (0.02 to 0.04)
Serotype 12F1.72 (1.40 to 2.12)0.33 (0.25 to 0.45)0.01 (0.01 to 0.01)
Serotype 15B11.21 (9.39 to 13.38)0.95 (0.74 to 1.21)0.03 (0.02 to 0.04)
Serotype 22F15.45 (13.24 to 18.03)8.66 (6.27 to 11.98)0.01 (0.00 to 0.01)
Serotype 33F4.94 (4.04 to 6.03)1.68 (1.21 to 2.34)0.02 (0.01 to 0.02)
SecondaryPercentage of Participants With Predefined IgG Concentrations for the 13 Matched Serotypes 1 Month After Last Vaccination

Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes:1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C,19A,19F, 23F. Predefined level was 0.35 mcg/mL for all 13vPnC serotypes except serotypes 5, 6B, and 19A, which had predefined levels of 0.23, 0.10, and 0.12 mcg/mL, respectively. 95% CI was based on the Clopper and Pearson method.

Time frame:
1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Predefined IgG Concentrations for the 13 Matched Serotypes 1 Month After Last Vaccination
Percentage of participants2-Dose 20vPnC1-Dose 20vPnC13vPnC Control
Serotype 194.1 (87.6 to 97.8)94.4 (88.3 to 97.9)98.1 (93.5 to 99.8)
Serotype 388.2 (80.4 to 93.8)87.0 (79.2 to 92.7)93.5 (87.1 to 97.4)
Serotype 498.0 (93.1 to 99.8)99.1 (94.9 to 100.0)100.0 (96.6 to 100.0)
Serotype 597.1 (91.6 to 99.4)96.3 (90.8 to 99.0)100.0 (96.6 to 100.0)
Serotype 6A100.0 (96.4 to 100.0)99.1 (94.9 to 100.0)99.1 (94.9 to 100.0)
Serotype 6B100.0 (96.4 to 100.0)98.1 (93.5 to 99.8)100.0 (96.6 to 100.0)
Serotype 7F100.0 (96.4 to 100.0)100.0 (96.6 to 100.0)100.0 (96.6 to 100.0)
Serotype 9V100.0 (96.4 to 100.0)99.1 (94.9 to 100.0)100.0 (96.6 to 100.0)
Serotype 14100.0 (96.4 to 100.0)99.1 (94.9 to 100.0)99.1 (94.9 to 100.0)
Serotype 18C100.0 (96.4 to 100.0)98.1 (93.5 to 99.8)99.1 (94.9 to 100.0)
Serotype 19A100.0 (96.4 to 100.0)100.0 (96.6 to 100.0)100.0 (96.6 to 100.0)
Serotype 19F100.0 (96.4 to 100.0)99.1 (94.9 to 100.0)100.0 (96.6 to 100.0)
Serotype 23F99.0 (94.7 to 100.0)99.1 (94.9 to 100.0)97.2 (92.1 to 99.4)
SecondarySerotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Last Vaccination

OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after last vaccination received. OPA titers below the LLOQ were set to 0.5\*LLOQ. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the Student's t distribution.

Time frame:
1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Reported as:
Geometric mean · Titers
Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Last Vaccination
Titers2-Dose 20vPnC1-Dose 20vPnC13vPnC Control
Serotype 146 (26 to 82)79 (47 to 133)105 (68 to 162)
Serotype 3131 (106 to 163)101 (72 to 142)128 (93 to 176)
Serotype 4348 (178 to 681)425 (213 to 845)541 (298 to 984)
Serotype 546 (30 to 69)77 (52 to 114)73 (52 to 104)
Serotype 6A1470 (1030 to 2096)1156 (768 to 1739)1796 (1286 to 2508)
Serotype 6B698 (437 to 1114)452 (275 to 743)790 (459 to 1357)
Serotype 7F1415 (844 to 2371)1212 (755 to 1945)1367 (790 to 2365)
Serotype 9V1719 (928 to 3185)1792 (1015 to 3166)1930 (1048 to 3556)
Serotype 14844 (474 to 1501)1245 (837 to 1852)558 (308 to 1011)
Serotype 18C1861 (1115 to 3106)1047 (583 to 1882)1149 (684 to 1930)
Serotype 19A512 (283 to 925)731 (401 to 1332)973 (560 to 1688)
Serotype 19F473 (257 to 873)470 (285 to 775)595 (363 to 975)
Serotype 23F727 (382 to 1382)472 (255 to 876)721 (439 to 1186)
Serotype 83446 (2282 to 5203)1609 (989 to 2617)76 (42 to 137)
Serotype 10A6783 (4555 to 10100)2506 (1425 to 4407)64 (40 to 104)
Serotype 11A3827 (1975 to 7414)3416 (1523 to 7665)235 (99 to 562)
Serotype 12F17398 (11121 to 27218)7346 (3895 to 13855)64 (34 to 122)
Serotype 15B10024 (6200 to 16206)3898 (1867 to 8136)58 (24 to 143)
Serotype 22F11820 (7993 to 17480)6117 (3289 to 11376)28 (13 to 61)
Serotype 33F43671 (28126 to 67809)15355 (9431 to 24998)694 (432 to 1115)

Adverse events

Collected over Local reactions and systemic events (systematic assessment): Within 7 days after Dose 1 and 2; All-cause mortality, SAEs and non-SAEs (non-systematic assessment): from Dose 1 to 1 month after Dose 1 (1-dose groups) or Dose 2 (2-dose group). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2-Dose 20vPnC (Dose 1 to Dose 2)0/121 (0%)4/121 (3.3%)93/121 (76.9%)
2-Dose 20vPnC (Dose 2 to 1 Month After Dose 2)0/116 (0%)1/116 (0.9%)91/116 (78.4%)
1-Dose 20vPnC (Dose 1 to 1 Month After Dose 1)0/118 (0%)1/118 (0.8%)90/118 (76.3%)
13vPnC Control (Dose 1 to 1 Month After Dose 1)0/117 (0%)1/117 (0.9%)98/117 (83.8%)
Most frequent serious events
Most frequent serious events
Event2-Dose 20vPnC (Dose 1 to Dose 2)2-Dose 20vPnC (Dose 2 to 1 Month After Dose 2)1-Dose 20vPnC (Dose 1 to 1 Month After Dose 1)13vPnC Control (Dose 1 to 1 Month After Dose 1)
RashSkin and subcutaneous tissue disorders0/1211/1160/1180/117
Lower respiratory tract infectionInfections and infestations1/1211/1160/1180/117
WheezingRespiratory, thoracic and mediastinal disorders0/1210/1160/1181/117
Thermal burnInjury, poisoning and procedural complications0/1210/1161/1180/117
Febrile convulsionNervous system disorders1/1210/1160/1180/117
BronchospasmRespiratory, thoracic and mediastinal disorders1/1210/1160/1180/117
BronchitisInfections and infestations1/1210/1160/1180/117
GastroenteritisInfections and infestations1/1210/1160/1180/117
Most frequent other events
Most frequent other events
Event2-Dose 20vPnC (Dose 1 to Dose 2)2-Dose 20vPnC (Dose 2 to 1 Month After Dose 2)1-Dose 20vPnC (Dose 1 to 1 Month After Dose 1)13vPnC Control (Dose 1 to 1 Month After Dose 1)
IrritabilityPsychiatric disorders70/12163/11660/11854/117
Injection site erythema (REDNESS)General disorders40/12130/11635/11838/117
Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders37/12129/11639/11831/117
Hypersomnia (INCREASED SLEEP)Nervous system disorders39/12127/11638/11837/117
Injection site pain (PAIN)General disorders33/12134/11634/11837/117
Injection site swelling (SWELLING)General disorders27/12127/11625/11830/117
Pyrexia (FEVER)General disorders20/12111/11618/11818/117
Upper respiratory tract infectionInfections and infestations18/1219/11613/1189/117

Baseline characteristics

Safety population included all participants who receive at least 1 dose of the study intervention and have safety data reported after any dose.

Age, Continuous
Age, Continuous(months)2-Dose 20vPnC1-Dose 20vPnC13vPnC ControlTotal
Mean12.5 ± 1.2112.6 ± 1.5212.7 ± 1.8512.6 ± 1.54
Age, Customized
Age, Customized(Participants)2-Dose 20vPnC1-Dose 20vPnC13vPnC ControlTotal
Infants and toddlers (28 days-23 months)121118117356
Sex: Female, Male
Sex: Female, Male(Participants)2-Dose 20vPnC1-Dose 20vPnC13vPnC ControlTotal
Female604757164
Male617160192
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)2-Dose 20vPnC1-Dose 20vPnC13vPnC ControlTotal
Hispanic or Latino343632102
Not Hispanic or Latino868285253
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)2-Dose 20vPnC1-Dose 20vPnC13vPnC ControlTotal
American Indian or Alaska Native0000
Asian0112
Native Hawaiian or Other Pacific Islander0000
Black or African American1012
White120117113350
More than one race0011
Unknown or Not Reported0011
08

Study locations

43 sites
  • Gyerkőc- Med Szolgáltató és Kereskedelmi Betéti Társaság
    Budapest, 1042, Hungary
  • Lurko-Med Kft Hazi Gyermekorvosi Rendelo
    Budapest, 1048, Hungary
  • Elitance Duo Kft.
    Budapest, 1188, Hungary
  • Private practice - Dr. Várhelyiné Dr. Torday Judit
    Debrecen, 4025, Hungary
  • Zsebibaba 2004 Bt. 8. Sz Gyermekkorzet
    Eger, 3300, Hungary
  • Mimiped Betéti Társaság
    Győr, 9024, Hungary
  • Futurenest Klinikai Kutató Kft.
    Miskolc, 3527, Hungary
  • Papp és Társa Egészségügyi és Szolgaltató Betéti Társaság
    Szigetvár, 7900, Hungary
  • MICS Centrum Medyczne Toruń
    Torun, Kujawsko-pomorskie 87-100, Poland
  • SZPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym
    Lomianki, Mazowieckie 05-092, Poland
  • Przylądek Zdrowia
    Krakow, Małopolskie 30-644, Poland
  • Rodzinne Centrum Medyczne LUBMED
    Lubon, Wielkopolskie 62-030, Poland
  • IN-VIVO Bydgoszcz
    Bydgoszcz, 85-048, Poland
  • SZPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym
    Dziekanów Leśny, 05-092, Poland
  • Pro Familia Altera Sp. z o.o.
    Katowice, 40-648, Poland
  • NZOZ Vita Longa Sp. z o.o.
    Katowice, 40-748, Poland
  • Przylądek Zdrowia
    Krakow, 30-644, Poland
  • Krakowski Szpital Specjalistyczny im. Jana Pawła II
    Krakow, 31-202, Poland
  • Specjalistyczny Zespol Opieki Zdrowotnej nad Matka i Dzieckiem w Poznaniu
    Poznan, 60-663, Poland
  • Specjalistyczny Zespół Opieki Zdrowotnej nad Matką i Dzieckiem w Poznaniu
    Poznań, 60-663, Poland
  • Centrum Medyczne Pratia Poznan
    Skorzewo, 60-185, Poland
  • MICS Centrum Medyczne Toruń
    Torun, 87-100, Poland
  • Szpital Bielanski im. Ks. Jerzego Popieluszki SPZOZ w Warszawie
    Warszawa, 01-809, Poland
  • Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu
    Wroclaw, 50-368, Poland
  • CHUS - Hospital Clinico Universitario
    Santiago de Compostela, A Coruña [LA Coruña] 15706, Spain
  • Hospital Germans Trias i Pujol
    Badalona, Barcelona [barcelona] 08916, Spain
  • Hospital Sant Joan de Déu
    Esplugues de Llobregat, Barcelona [barcelona] 08950, Spain
  • Hospital Sant Joan de Déu
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Hospital Universitari General de Catalunya
    Sant Cugat del Vallès, Barcelona 08195, Spain
  • EAP Osona Sud - Alt Congost S.L.P
    Centelles, Catalunya [cataluña] 08500, Spain
  • Hospital Clinico Universitario Santiago de Compostela
    Santiago de Compostela, LA Coruña 15706, Spain
  • CHUS - Hospital Clinico Universitario
    Santiago de Compostela, LA Coruña 15760, Spain
  • Hospital Universitario HM Puerta del Sur
    Madrid, Madrid, Comunidad DE 28938, Spain
  • Hospital Universitario HM Monteprincipe
    Boadilla del Monte, Madrid 28660, Spain
  • Grupo Pediatrico Uncibay
    Malaga, Málaga 29015, Spain
  • Hospital de Nens de Barcelona
    Barcelona, 08009, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28009, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28009, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
  • Grupo Pediatrico Uncibay
    Malaga, 29015, Spain
  • Instituto Hispalense de Pediatria
    Sevilla, 41012, Spain
  • Instituto Hispalense de Pediatria
    Sevilla, 41014, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jun 2023, 11 months.

Results were first posted in Sep 2024, 1 year 3 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 11 months is close to that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2022
First posted
Jun 7, 2022
StartActual
Jun 24, 2022
Primary completionActual
Jun 1, 2023
CompletionActual
Jun 1, 2023
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05408429
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 7, 2022
Start date
Jun 24, 2022
Primary completion
Jun 1, 2023
Completion
Jun 1, 2023
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion